Aziz Mottiwala becomes RxSight CEO July 20 amid commercial challenges. The move follows the $200M Alcon deal for adjustable ...
Collaboration aims to combine best-in-class PCIOL optics with first-in-class platform to enable fine-tuning of visual outcomes after cataract surgery. (PRESS RELEASE) ALISO VIEJO, CA — Alcon, the ...
RxSight (NASDAQ:RXST) reported preliminary second-quarter financial results and provided updates on its product pipeline ...
Alcon and RxSight, Inc have announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting ...
Alcon's $200M RxSight partnership aims to recapture IOL market share with adjustable presbyopic lenses. RxSight gets 30% ...
Alcon and RxSight announced a nonexclusive collaboration to develop a light-adjustable presbyopia-correcting IOL, according ...
Over the last several years, the RxSight team has been developing proprietary hybrid IOL materials for next-generation light adjustable technology that can support a full suite of adjustable lenses ...
Medical Device Network on MSN
Alcon spends up to $200M to co-develop customisable cataract lenses with RxSight
The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for ...
RxSight, Inc. (NASDAQ: RXST) today announced select preliminary financial results for the second quarter of 2026 and updates to its standalone product pipeline, following the announcement of the ...
Alcon's new platforms, lenses and dry eye momentum support growth, but macro pressures, tariffs and fierce competition weigh on its outlook.
“With the full U.S. availability of TECNIS PureSee IOL, we are expanding access to an important extended depth of focus option that reflects our commitment to innovation, visual quality, and patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results